News for Prothena Corporation plc (PRTA)

Prothena Corporation is advancing Birtamimab for AL amyloidosis. Learn why PRTA stock is risky with uncertain upcoming data and past trial disappointments.

Prothena Corporation plc (NASDAQ:PRTA) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsMark Johnson - Vice President of...

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Pro

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Prothena stock soars despite study miss

U.S. stocks were higher, with the Dow Jones index gaining over 150 points on Thursday. Shares of Accenture plc ACN rose sharply in today's session after the co...

Prothena (PRTA) stock gains even as Parkinson's disease therapy developed with Roche (RHHBY) misses primary endpoint in mid-stage trial. Read more here,

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful Phase 1 data for PRX012. Read more here.

The rising incidence of Alzheimer's and other tau-related disorders, driven by an aging global population, is significantly boosting the demand for...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday. The Dow traded down 0.71% to 42,012.42...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. The Dow traded down 0.55% to 42,079.06...

The growing demand for corporate wellness is largely driven by factors such as increased screen time, higher workloads, rapid urbanization, poor diet,...

We recently compiled a list of the 7 Best Debt Free Stocks To Buy.

The surge in neuroendoscopy demand is chiefly fueled by the increasing occurrence of neurological conditions like brain tumors. Furthermore, the escalating...

Discover 21 new analysts who joined Seeking Alpha in June.

The PDE4 inhibitor market is poised for substantial growth in the coming years, driven by expanding research in inflammatory and autoimmune diseases. With...

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

DelveInsight’s analysts estimate that the traumatic brain injury market is expected to show positive growth, mainly attributed to increasing incidence,...